You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 8, 2024

Claims for Patent: 8,980,873

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,980,873

Title:	11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.- 1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
Abstract:	The present invention relates to certain salts of a 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1- .1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (Compound I) which have been found to have improved properties. In particular the present invention relates to the citrate salt of this compound. The invention also relates to pharmaceutical compositions containing the citrate salt and methods of use of the citrate salt in the treatment of certain medical conditions. ##STR00001##
Inventor(s):	Dymock; Brian (Singapore, SG), Lee; Cheng H. (Singapore, SG), William; Anthony D. (Singapore, SG)
Assignee:	CTI Biopharma Corp. (Seattle, WA)
Application Number:	13/133,297
Patent Claims:	1. A crystalline citrate salt of 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1- .1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene which shows on X-ray diffraction a peak on the 2theta scale at 22.4.degree..+-.0.5.degree.. 2. A salt according to claim 1 wherein the salt is the 1:1 salt. 3. A salt according to claim 1 which also shows on X-ray diffraction peaks on the 2theta scale at 10.2.degree..+-.0.5.degree. and 15.7.degree..+-.0.5.degree.. 4. A salt according to claim 1 which shows on X-ray diffraction at least four peaks on the 2theta scale selected from the group consisting of 7.8.degree..+-.0.5.degree., 10.2.degree..+-.0.5.degree., 14.2.degree..+-.0.5.degree., 15.7.degree..+-.0.5.degree., 16.8.degree..+-.0.5.degree., 21.4.degree..+-.0.5.degree., and 22.4.degree..+-.0.5.degree.. 5. A salt according to claim 4 which shows on X-ray diffraction at least 6 peaks on the 2theta scale selected from the group consisting of 7.8.degree..+-.0.5.degree., 10.2.degree..+-.0.5.degree., 14.2.degree..+-.0.5.degree., 15.7.degree..+-.0.5.degree., 16.8.degree..+-.0.5.degree., 21.4.degree..+-.0.5.degree., and 22.4.degree..+-.0.5.degree.. 6. A salt according to claim 4 which shows on X-ray diffraction peaks on the 2theta scale at 7.8.degree..+-.0.5.degree., 10.2.degree..+-.0.5.degree., 14.2.degree..+-.0.5.degree., 15.7.degree..+-.0.5.degree., 16.8.degree..+-.0.5.degree., 21.4.degree..+-.0.5.degree., and 22.4.degree..+-.0.5.degree.. 7. A salt according to claim 6 which also shows on X-ray diffraction peaks on the 2theta scale at 10.9.degree..+-.0.5.degree., 17.1.degree..+-.0.5.degree., 23.3.degree..+-.0.5.degree., 25.1.degree..+-.0.5.degree., 25.8.degree..+-.0.5.degree., and 27.5.degree..+-.0.5.degree.. 8. A salt according to claim 7 which also shows on X-ray diffraction peaks on the 2theta scale at 7.2.degree..+-.0.5.degree., 17.6.degree..+-.0.5.degree., 18.5.degree..+-.0.5.degree., 18.7.degree..+-.0.5.degree., 20.7.degree..+-.0.5.degree., 23.1.degree..+-.0.5.degree., 24.2.degree..+-.0.5.degree., 26.2.degree..+-.0.5.degree., 26.9.degree..+-.0.5.degree., 28.7.degree..+-.0.5.degree., 29.3.degree..+-.0.5.degree., 31.0.degree..+-.0.5.degree., 32.4.degree..+-.0.5.degree., 37.3.degree..+-.0.5.degree., 38.6.degree..+-.0.5.degree., 39.9.degree..+-.0.5.degree.and 41.6.degree..+-.0.5.degree.. 9. A pharmaceutical composition comprising a salt according to claim 1. 10. A method of treating cancer comprising administration of a therapeutically effective amount of a salt according to claim 1 to a patient in need thereof, wherein the cancer is selected from the group consisting of colon cancer, acute myeloid leukaemia and myelofibrosis. 11. A method according to claim 10 wherein the cancer is colon cancer. 12. A method according to claim 10 wherein the cancer is acute myeloid leukaemia. 13. A method according to claim 10 wherein the cancer is myelofibrosis.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.